Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03943901 · ClinicalTrials.gov registry record · Phase 2

Split-Dose R-CHOP for Older Adults With DLBCL

A Phase 2 study of Cancer and Diffuse Large B Cell Lymphoma, sponsored by University of Wisconsin, Madison.

Active
Registry status
Phase 2
Development phase
27
Enrollment target
1
Study location

NCT03943901 is a Phase 2 study of Cancer and Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 27 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03943901, a Phase 2 study of Cancer and Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).

Conditions Studied

Cancer Diffuse Large B Cell Lymphoma DLBCL

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Rituximab
  • DRUG Vincristine
  • DRUG Prednisone

Study Locations (1)

Wisconsin

  • University of Wisconsin Carbone Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2021-02-17
Est. Completion 2027-02
Phase Phase 2

Sponsor

University of Wisconsin, Madison

1,039 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03943901

The ClinicalTrials.gov registry entry for NCT03943901 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT03943901 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03943901 about?

NCT03943901 is a clinical study titled "Split-Dose R-CHOP for Older Adults With DLBCL". This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 ...

What is the current status of trial NCT03943901?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2021-02-17. Estimated completion is 2027-02.

What conditions does trial NCT03943901 study?

This clinical trial studies the following conditions: Cancer, Diffuse Large B Cell Lymphoma, DLBCL.

What interventions are being tested in trial NCT03943901?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), Prednisone (DRUG).

Who is sponsoring clinical trial NCT03943901?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03943901 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.